The promising results from combinational citrullinated ENO1 and Vim peptides also should be further explored with chemotherapeutic targets in pilot clinical trials for their immunogenicity and safety in cancer patients, to open new possibilities of design immunotherapeutic strategies. The gene discussed is VIM; the disease is cancer.